Selecta to develop synthetic malaria vaccine

Science Applications International Corporation has awarded Selecta Biosciences, Inc., a biopharmaceutical company specializing in vaccines and immunotherapies, a subcontract to develop a targeted synthetic vaccine for malaria on Wednesday.

The funding will be provided by SAIC through its Malaria Vaccine Production and Support Services contract with the National Institute of Allergy and Infectious Diseases, which is a division of the National Institutes of Health. The targeted Synthetic Vaccine Particle vaccine for malaria will be developed by Selecta for testing in preclinical studies by SAIC collaborators.

"We are extremely pleased that we have been selected to apply our novel vaccine platform to the development of a vaccine for malaria," Werner Cautreels, the president and CEO of Selecta Biosciences, said. "This collaboration accelerates our progress to apply Selecta's advanced vaccine technology to address the significant unmet medical needs in malaria and highlights the breadth of our vaccine technology to treat a range of diseases that impact human health, including infectious diseases, autoimmune diseases, and smoking cessation."

The subcontract is part of a collaborative effort by the U.S. Agency for International Development and NIAID to jointly develop novel vaccines and therapeutics for malaria.

tSVP vaccines are fully-integrated synthetic nanoparticle vaccines that are engineered to mimic the properties of natural pathogens to elicit a maximal immune response. Selecta designs tSVP products to deliver adjuvant and antigen combinations within the same biodegradable nanoparticle, ensuring a durable and focused response while keeping off-target effects at a low level.

Organizations in this story

U.S. Agency for International Development 1300 Pennsylvania Ave NW Washington, DC 20004

National Institutes of Health 9000 Rockville Pike Bethesda, MD 20892

Get notified the next time we write about any of these organizations